The Pharma Scoop: Vanda Meets Endpoints, Aratana To Be Acquired, Einhorn Invests In NeuBase [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
The Pharma Scoop: Vanda Meets Endpoints, Aratana To Be Acquired, Einhorn Invests In NeuBase Summary Vanda saw success in a trial of tradipitant in motion sickness. Aratana is making moves to be acquired by Elanco, creating a pet medicine behemoth. Billionaire investor Einhorn has invested in a recent IPO called NeuBase. Avisol is starting the Pharma Scoop after a long gap and hopes to be able to continue this popular publication. Welcome to another edition of the Pharma Scoop, a regular piece featuring offbeat news from undercovered stocks. This is brought to you by Avisol Capital Partners; we run the Total Pharma Tracker Vanda Pharmaceuticals ( VNDA announced Source In an exploratory analysis, tradipitant showed statistically significant difference versus the placebo in "rough sea" conditions. 72.2% (n=13/18) of the control group experienced vomiting, while only 15.8% (n=3/19) of the tradipitant treated population displayed vomiting syndromes. Primary endpoint on percentage of partic
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035: A USD 66.63 Billion Market by 2035, Up From USD 9.03 Billion in 2022 [Yahoo! Finance]Yahoo! Finance
- Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics [Yahoo! Finance]Yahoo! Finance
- American Kidney Fund Launches National Kidney Health Equity Media Campaign [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk comes under Senate probe over pricing for weight loss drugs [Seeking Alpha]Seeking Alpha
- Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings? [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/6/24 - Miss
LLY
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- LLY's page on the SEC website